ES2648876T3 - Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo - Google Patents
Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo Download PDFInfo
- Publication number
- ES2648876T3 ES2648876T3 ES14744029.1T ES14744029T ES2648876T3 ES 2648876 T3 ES2648876 T3 ES 2648876T3 ES 14744029 T ES14744029 T ES 14744029T ES 2648876 T3 ES2648876 T3 ES 2648876T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- methyl
- substituted once
- twice
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13177539 | 2013-07-23 | ||
EP13177539 | 2013-07-23 | ||
PCT/EP2014/065605 WO2015011084A1 (de) | 2013-07-23 | 2014-07-21 | Substituierte dihydropyrido[3,4-b]pyrazinone als duale inhibitoren von bet-proteinen und polo-like kinasen |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2648876T3 true ES2648876T3 (es) | 2018-01-08 |
Family
ID=48832802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES14744029.1T Active ES2648876T3 (es) | 2013-07-23 | 2014-07-21 | Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo |
Country Status (8)
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
JP6461118B2 (ja) | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | ブロモドメイン阻害剤としての新規の置換された二環式化合物 |
SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
KR20160038008A (ko) | 2013-07-31 | 2016-04-06 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 억제제로서 신규 퀴나졸리논 |
CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
CA2966303A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
EP3230277B1 (en) | 2014-12-11 | 2019-09-18 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
EP3233846A4 (en) | 2014-12-17 | 2018-07-18 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
CN108601764A (zh) | 2015-03-18 | 2018-09-28 | 阿尔维纳斯股份有限公司 | 用于靶蛋白的增强降解的化合物和方法 |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
WO2016207345A1 (en) * | 2015-06-24 | 2016-12-29 | Pierre Fabre Medicament | 3-amino-pyrazin-2-yl carboxamide and 2-amino-pyridin-3-yl carboxamide derivatives as polo-like kinase 1 (plk-1) inhibitors for the treatment of cancer |
CA2995036A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
KR101796779B1 (ko) | 2015-12-22 | 2017-11-10 | 한국화학연구원 | 다이하이드로프테리딘-온 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
CN111386263A (zh) | 2017-02-08 | 2020-07-07 | 达纳-法伯癌症研究所有限公司 | 调节嵌合抗原受体 |
CN106977584B (zh) * | 2017-04-19 | 2019-12-06 | 吉林大学 | 靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
WO2018207881A1 (ja) * | 2017-05-12 | 2018-11-15 | 武田薬品工業株式会社 | 複素環化合物 |
US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
CN118480030A (zh) | 2018-04-13 | 2024-08-13 | 阿尔维纳斯运营股份有限公司 | 小脑蛋白配体和包括其的双官能化合物 |
CN109096276B (zh) * | 2018-08-01 | 2021-05-28 | 上海博志研新药物技术有限公司 | 盐酸莫西沙星及其中间体的制备方法 |
WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
TW202136240A (zh) | 2019-12-19 | 2021-10-01 | 美商亞文納營運公司 | 用於靶向降解雄激素受體之化合物及方法 |
CN115947728B (zh) * | 2021-10-09 | 2024-01-09 | 沈阳药科大学 | 含磺酰基的二氢喋啶酮衍生物及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
WO2006021548A1 (de) * | 2004-08-27 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US20110207796A1 (en) * | 2008-02-13 | 2011-08-25 | Elan Pharma International Limited | Alpha-synuclein kinase |
JP5913292B2 (ja) * | 2010-05-14 | 2016-04-27 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 代謝を調節する組成物および方法 |
WO2012075456A1 (en) * | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
JP2015501793A (ja) * | 2011-11-10 | 2015-01-19 | オーエスアイ・ファーマシューティカルズ,エルエルシー | ジヒドロプテリジノン類 |
-
2014
- 2014-07-21 CN CN201480052256.5A patent/CN105555786A/zh active Pending
- 2014-07-21 JP JP2016528479A patent/JP2016525135A/ja not_active Withdrawn
- 2014-07-21 EP EP14744029.1A patent/EP3027614B1/de not_active Not-in-force
- 2014-07-21 WO PCT/EP2014/065605 patent/WO2015011084A1/de active Application Filing
- 2014-07-21 ES ES14744029.1T patent/ES2648876T3/es active Active
- 2014-07-21 US US14/907,367 patent/US20160272635A1/en not_active Abandoned
- 2014-07-21 CA CA2918813A patent/CA2918813A1/en not_active Abandoned
-
2016
- 2016-08-25 HK HK16110129.5A patent/HK1221952A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3027614A1 (de) | 2016-06-08 |
HK1221952A1 (zh) | 2017-06-16 |
JP2016525135A (ja) | 2016-08-22 |
CN105555786A (zh) | 2016-05-04 |
US20160272635A1 (en) | 2016-09-22 |
WO2015011084A1 (de) | 2015-01-29 |
CA2918813A1 (en) | 2015-01-29 |
EP3027614B1 (de) | 2017-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2648876T3 (es) | Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo | |
ES2635003T3 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas inhibidoras de proteína BET | |
US20150376196A1 (en) | 4-substituted pyrrolo- and pyrazolo-diazepines | |
CA2901799A1 (en) | Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases | |
US20160193206A1 (en) | Bet-protein-inhibiting dihydropyridopyrazinones | |
TWI574962B (zh) | 作爲pi3激酶調節劑的芳雜環化合物及其使用方法和用途 | |
US20150344444A1 (en) | Bet-protein-inhibiting dihydroxyquinoxalinones | |
CA2846692A1 (en) | 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines | |
CN105732637B (zh) | 杂芳化合物及其在药物中的应用 | |
TW202340209A (zh) | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 | |
US20170121322A1 (en) | Bet-protein inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino- or ether groups | |
WO2015193228A1 (de) | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe | |
WO2015193217A1 (de) | Bet-proteininhibitorische dihydropyrido[2,3-b]pyrazinon-derivate mit para-substituierter aromatischer amino- oder ethergruppe | |
WO2015193229A1 (de) | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe |